Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Statins under California Prop 65

Executive Summary

California's Office of Environmental Health Hazard Assessment should assess toxicological studies on each member of the statin class of cholesterol drugs, California Carcinogen Committee recommended at Dec. 17 meeting. OEHHA will present to committee on consideration of each drug for placement on Proposition 65 carcinogen list at 2003 or 2004 annual meeting. Merck's Mevacor (lovastatin) was picked for consideration at random, but Merck petitioned committee to consider the statins as a group (1"The Pink Sheet" Dec. 9, 2002, p. 22)...

You may also be interested in...



Mevacor, Other Statins To Be Considered By California Carcinogen Committee

California's Carcinogen Identification Committee will evaluate during its Dec. 17 meeting whether all statins should be designated as carcinogens under Proposition 65, rather than Merck's Mevacor (lovastatin) alone

Vaccine Company CEOs Face Supply Probe In EU

AstraZeneca's CEO and other leaders from COVID-19 vaccine companies will face some tough questions in Brussels, but the European Commission wants to put differences behind it and solve the vaccine supply problem as soon as possible.

Trial Shows Lateral Flow Antibody Testing Could Be Used To Assess COVID-19 Vaccine Efficacy

Abingdon Health has announced that a study run in conjunction with the UK Rapid Test Consortium has demonstrated that its AbC-19 test could be an effective tool for testing vaccine efficacy. 

UsernamePublicRestriction

Register

LL1131980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel